5.33 USD
-0.06 (-1.11%)
5.44 USD
+0.11 (+2.06%)
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. This makes MDXG very considerable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year MDXG was profitable.
- In the past year MDXG had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
- In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
- MDXG's Return On Assets of 12.80% is amongst the best of the industry. MDXG outperforms 94.48% of its industry peers.
- MDXG has a Return On Equity of 17.09%. This is amongst the best in the industry. MDXG outperforms 95.05% of its industry peers.
- MDXG has a better Return On Invested Capital (15.15%) than 95.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of MDXG (10.38%) is better than 91.43% of its industry peers.
- With an excellent Operating Margin value of 13.73%, MDXG belongs to the best of the industry, outperforming 92.95% of the companies in the same industry.
- In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
- The Gross Margin of MDXG (81.99%) is better than 85.71% of its industry peers.
- In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
- MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, MDXG has more shares outstanding
- MDXG has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 8.26 indicates that MDXG is not in any danger for bankruptcy at the moment.
- MDXG's Altman-Z score of 8.26 is fine compared to the rest of the industry. MDXG outperforms 79.62% of its industry peers.
- MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.27, MDXG belongs to the top of the industry, outperforming 95.43% of the companies in the same industry.
- MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
- MDXG has a worse Debt to Equity ratio (0.07) than 60.95% of its industry peers.
- Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 8.26 |
ROIC/WACC1.72
WACC8.81%
2.3 Liquidity
- A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
- MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.86% of its industry peers.
- MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- MDXG has a Quick ratio (3.95) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
- The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
- The Revenue has grown by 14.77% in the past year. This is quite good.
- The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
- MDXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.54% yearly.
- MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.49% yearly.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 14.81, MDXG is valued correctly.
- Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 96.19% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of MDXG to the average of the S&P500 Index (27.32), we can say MDXG is valued slightly cheaper.
- Based on the Price/Forward Earnings ratio of 21.33, the valuation of MDXG can be described as rather expensive.
- MDXG's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 93.14% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.30. MDXG is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.81 | ||
| Fwd PE | 21.33 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaper than 97.33% of the companies in the same industry.
- 97.71% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.82 | ||
| EV/EBITDA | 9.82 |
4.3 Compensation for Growth
- MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MDXG may justify a higher PE ratio.
- A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
- MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.33
-0.06 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners71.94%
Inst Owner Change0.21%
Ins Owners1.79%
Ins Owner Change-0.11%
Market Cap789.37M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (133.4%)
Short Float %3.7%
Short Ratio6.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)0%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.81 | ||
| Fwd PE | 21.33 | ||
| P/S | 2.01 | ||
| P/FCF | 11.82 | ||
| P/OCF | 11.64 | ||
| P/B | 3.3 | ||
| P/tB | 3.79 | ||
| EV/EBITDA | 9.82 |
EPS(TTM)0.36
EY6.75%
EPS(NY)0.25
Fwd EY4.69%
FCF(TTM)0.45
FCFY8.46%
OCF(TTM)0.46
OCFY8.59%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.31
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 8.26 |
F-Score6
WACC8.81%
ROIC/WACC1.72
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.
What is the earnings growth outlook for MIMEDX GROUP INC?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 47.72% in the next year.